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Abstract:
Background: There is a direct correlation between glycemic load and the risk of developing many malignant neoplasms.
Aims: The aim of this study was to determine the plasma glucose levels in women with cervical cancer.
Methods: The study included 177 women with anatomopathologically diagnosed uterine cervical cancer (stages 0–IV) treated between 
1980 and 2008 at the Gynecology and Obstetrics outpatient service of the UFTM, Brazil. The plasma glucose levels of all patients were 
assayed at the time of diagnosis and correlated with tumor staging.
Results: We statistically compared the plasma glucose levels of group 1 (cervical intraepithelial neoplasia 2–3), group 2 (stage I–II), 
group 3 (stage III–IV), and group 4 (control group: leiomyomas). Patient groups with poor prognosis (groups 2 and 3) showed   significantly 
higher plasma glucose levels (P , 0.05) than those with less aggressive lesions (group 1). Plasma glucose levels were   significantly 
higher in groups 2 and 3 than in group 4 (P , 0.05). The comparison of number of patients with plasma glucose level .90 mg/dl showed 
CIN versus I/II: P = 0.0753; OR = 2.018; (95% CI: 0.9236 to 4.410) and CIN versus III/IV: P = 0.0975; OR = 2.400; (95% CI: 0.8335 
to 6.911).
Conclusion: We observed an association between high plasma glucose levels and cervical cancer cases with poor prognoses. Plasma 
glucose tests should be routinely used as additional prognostic parameters in patients with cervical neoplasias.
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Introduction
Cervical  cancer  is  a  public  health  problem  in 
  developing countries, characterized by high preva-
lence and mortality rates in premenopausal women of 
low socioeconomic status.1 Factors related to glucose 
metabolism  may  play  an  important  role  in  cancer 
development. The glycemic index has been investi-
gated as a potential etiological and prognostic factor 
for several types of malignancy.2
The literature shows a direct correlation between 
glycemic  load/glycemic  index  and  the  risk  of 
developing colorectal,2–5 breast,6,7 upper aerodiges-
tive  tract,8  gastric,9  ovarian,10–12  and  endometrial 
cancer.2,13,14  However,  to  our  knowledge,  no  pub-
lished study has investigated plasma glucose level 
as a cofactor in the progression of noninvasive cer-
vical lesions to invasive carcinomas, or the role of 
plasma glucose evaluation in the prognosis of this 
neoplasia. The  aim  of  this  study  was  to  examine 
the relationship between plasma glucose levels and 
cervical cancer staging, and the applicability of this 
measure as a prognostic factor.
patients and Methods
Patients and controls
This retrospective study was carried out at the Onco-
logical  Research  Institute  (IPON),  Discipline  of 
Gynecology and Obstetrics, of the Federal University 
of Triângulo Mineiro (UFTM). Data were collected 
from the medical records of 177 women with anato-
mopathologically  diagnosed  uterine  cervical  neo-
plasia (stages 0–IV) attending the Gynecology and 
Obstetrics outpatient service of the UFTM between 
1980 and 2008. Patients with HIV coinfection, those 
who had used corticosteroids during the period of 
the disease, and those diagnosed with diabetes melli-
tus were excluded from the study. This research was 
approved by the Research Ethics Committee of the 
UFTM.
The patients were divided into three groups accord-
ing to the staging system of the International Federa-
tion of Gynecology and Obstetrics (FIGO): group 1 
(n  =  104):  cervical  intraepithelial  neoplasia  (CIN) 
2–3 (stage 0); group 2 (n = 48): invasive cervical car-
cinoma stages I–II; group 3 (n = 25): invasive cervi-
cal carcinoma stages III–IV. A fourth group (n = 100) 
consisted  of  randomly  chosen  patients  diagnosed 
with uterine leiomyoma that had been confirmed by 
postoperative histopathological examination.
Plasma glucose levels
Blood samples were collected from patients during 
routine preoperative testing for the measurement of 
plasma  glucose  levels  (mg/dl).  The  patients  fasted 
for 12 hours before sample collection. Plasma glu-
cose levels were correlated with neoplasm staging in 
groups 1–3, and these three groups were then com-
pared with group 4.
Statistical analysis and ethical approval
Data were analyzed using GraphPad Instat software. 
Values were expressed as means ± standard deviations 
(SD). The unpaired t test was used to compare pairs 
of groups, with P values of less than 0.05 considered 
to  indicate  statistical  significance.  Plasma  glucose 
cut off level of 90 mg/dl to calculate the Odds Ratio 
(OR-95% confidence interval-CI). The research was 
approved by Ethical Committee of UFTM.
Results
Table  1  shows  the  characteristics  of  the  study 
patients.
Table 2 presents the mean plasma glucose   levels 
of  patients  in  all  groups.  Plasma  glucose  levels 
(mg/dl) in groups 1–4 were 94.7 ± 14.1, 104.3 ± 31.4, 
112.6 ± 56.7, and 94.5 ± 13.4 mg/dl, respectively. 
We  observed  that  patient  groups  with  poor  prog-
noses (groups 2 and 3) showed significantly higher 
plasma glucose levels (group 2: P = 0.011, group 3: 
P = 0.0044) than those with less aggressive lesions 
(group 1). We also compared patients with cervical 
neoplasia (groups 1–3) to patients with leiomyomas 
(group 4). Plasma glucose levels were significantly 
higher in groups 2 and 3 (P = 0.009, P = 0.0041, 
respectively) than in the leiomyoma group.
The OR values are shown in Table 2. There is a ten-
dency to significant difference statistic for comparison 
of blood glucose above 90 mg/dl in patients with inva-
sive staging in relation to the group with CIN.
Discussion
Diets  with  high  glycemic  loads  have  been  directly 
associated  with  the  risk  of  diverse  chronic  condi-
tions,  such  as  diabetes,15  coronary  heart  disease,16 Plasma glucose and uterine cervical neoplasias
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and cancer.2 Hyperinsulinemia may be implicated in 
the mechanism by which high glycemic load leads to 
these diseases.10
Our  study  aimed  to  evaluate  glucose  levels  in 
patients with cervical cancer, since this parameter 
is simpler than the dosage load and glycemic index, 
parameters that are already linked to several types of 
cancer in the literature. Data of the 177 patients were 
collected from 1980–2008. During this long period, 
there were no significant changes in the methods of 
plasma collection and glucose tests in the clinical 
laboratory of our university over time. The collec-
tion has been carried out with 12 hours of fasting for 
many years. The main changes that occurred were the 
cutoff levels for the diagnosis of glucose intolerance 
or diabetes, but that does not interfere in our study, 
because it compared glucose levels in each group, no 
cut off. In the literature, a meta-analysis of the role 
of glycemic index and load in cancer risk suggested 
a direct association for colorectal and endometrial 
cancer and an inconsistent relationship with several 
other types of cancer. Obesity was a major determi-
nant of insulin resistance and hyperinsulinemia, and 
physical  activity  influenced  glucose  tolerance  and 
insulin sensitivity.2
Uterine cervical cancer is related to human papil-
lomavirus (HPV),17 and HPV infection is   considered 
a causal factor in the development of CIN and inva-
sive  neoplasia.18  Persistent  infection  of  the  geni-
tal  tract  with  oncogenic  subtypes  of  HPV  is  the 
leading  cause  of  squamous  intraepithelial  lesions 
and invasive carcinoma.19,20 The presence of HPV 
does  not    establish  clinical  disease  presence,  and 
rarely   persists or progresses to high-grade disease. 
  Progression  to  invasion  depends  on  additional 
cofactors,  such  as  nicotine,  exogenous  estrogen, 
p53 polymorphism, immune status, or the presence 
of other infectious agents.21 Thus, the discovery of 
other  factors  in    carcinogenesis  of  cervical  cancer 
could lead to new   targets of study for the treatment 
and prognosis.
The consumption of a diet rich in glucose may 
lead  to  chronic  hyperinsulinemia  and  insulin 
resistance,10,22  which  have  been  shown  to  reduce 
concentrations of insulin-like growth factor binding 
protein (IGFBP) and consequently increase insulin-
like growth factor-1 (IGF-1) levels. Some studies 
have shown that increased IGF-1 activity inhibits 
apoptosis  and  stimulates  cell  proliferation;  these 
factors may lead to the development of cancer. High 
IGF-1 activity also increases steroid synthesis and 
inhibits hormone-binding globulin synthesis, con-
tributing to the development of ovarian and endo-
metrial cancer.23,24





Group 3  
(stages III–IV)
Group 4  
(leiomyomas)
Patients (n) 104 48 25 100
Age [years; mean (range)] 39.8 (23–69) 43.9 (32–71) 48.6 (43–75) 46.5 (32–77)
Parity [children; mean (range)] 3.8 (0–10) 4.7 (1–11) 6.5 (0–14) 3.9 (0–9)
Table 2. Age and plasma glucose levels in patients with cervical intraepithelial neoplasia (CIn; group 1), uterine cervical 





Group 3  
(stages III–IV)
Group 4  
(leiomyomas)
Patients (n) 104 48 25 100
Plasma glucose level (mg/dl) 94.7 ± 14.1* 104.3 ± 31.4 112.6 ± 56.7 94.5 ± 13.4**
Plasma glucose level , 90 mg/dl (n, %) 39–37.5 11–22.9 5–20 35–35
Plasma glucose level $ 90 mg/dl (n, %) 65 – 62.5 37–77.1 20–80 65–65
notes: *P = 0.0110 vs. group 2, P = 0.0044 vs. group 3; **P = 0.0090 vs. group 2, P = 0.0041 vs. group 3. Chi-square test: CIn versus I/II: P = 0.0753; 
Or = 2.018; (95% CI: 0.9236 to 4.410); CIn versus III/IV:P = 0.0975; Or = 2.400; (95% CI: 0.8335 to 6.911); I/II versus III/IV: P = 0.7750; Or = 1.189; (95% 
CI: 0.3621 to 3.906); Leiomyomas versus CIn 2/3: P = 0.7104; Or = 0.8974 (95% CI: 0.5068 to 1.589); Leiomyomas versus I/II: P = 0.1371; Or = 1.811 
(95% CI: 0.8230 to 3.986); Leiomyomas versus III/IV: P = 0.1504; Or = 2.154 (95% CI: 0.7440 to 6.235).nomelini et al
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In  colorectal  cancer,  insulin  receptors  activate 
mitogenic  signaling  pathways,  increasing  the  risk 
of cancer in patients with elevated insulin levels (as 
occurs in insulin resistance and non-insulin-dependent 
diabetes).25  Insulin  is  inversely  associated  with 
IGFBP-1.26,27 Several studies have associated indica-
tors of insulin resistance, including serum levels of 
insulin, C-peptide, glycated hemoglobin, and   glucose, 
with colorectal neoplasia.28–30
Obesity and insulin resistance are the results of 
compromised insulin signaling in liver, muscle, and 
adipose tissue, likely due to elevated levels of free 
fatty  acids  or  cytokines  from  adipose  tissue  (eg, 
tumor necrosis factor-α) that antagonize phosphory-
lation events at the insulin receptor.31 The pancreas 
compensates by up-regulating insulin synthesis, and 
  tissues that express insulin receptors (eg, colon tis-
sue) may be chronically exposed to increased levels 
of insulin, free fatty acids, and glucose, with sub-
sequent  mitogenic  and  tumor-promoting  effects.32 
Since high blood glucose levels may be a predispos-
ing factor for the development of insulin resistance 
or diabetes mellitus, our findings are consistent with 
the   literature, and a positive association may exist 
between this parameter and cervical cancer. Besides, 
we have added group 4 thinking about the interference 
of age as a factor in the increase of plasma glucose 
and increased incidence of cancer. Even with a mean 
age similar to groups 2 and 3, and leiomyoma being 
a  benign  disease,  we  found  statistical  significance 
when compared glucose levels with these patients of 
groups 2 and 3. This finding may suggest a stronger 
relation with the progression of the disease than with 
the increasing age of the patients.
Genetic alterations may be associated with insulin 
resistance and the development of cancer. Preliminary 
evidence has been shown for the interaction between 
genetic variation in insulin receptors and body mass 
index  in  the  risk  for  advanced  left-sided  colorectal 
adenoma.33
Women  with  diabetes  have  been  shown 
to  be  at  higher  risk  for  breast  cancer.34  Their 
high-glycemic-load  diets  have  reduced  the  levels 
of adiponectin, an adipocyte-produced insulin sen-
sitizer35  that  is  inversely  associated  with  obesity. 
Decreased concentrations of adiponectin have been 
related  to  an  increase  in  postmenopausal  breast 
cancer  risk,  independent  of  IGF-I  and  IGFBP-3 
concentrations.36,37 Lajous et al showed an increase in 
the risk of estrogen-receptor-negative breast cancer 
with increasing carbohydrate and dietary glycemic 
load  intakes.38  Sieri  et  al  found  a  direct  associa-
tion between glycemic load and breast   cancer risk 
in premenopausal women who reported low levels 
of physical activity.39 In contrast,   Mulholand et al 
showed that glycemic load and index were not rel-
evant    etiological  factors  for  breast  cancer.40  Diets 
with high   glycemic loads have been associated with 
an increased risk of endometrial cancer, more pro-
nounced  in  obese  women,  but  additional  research 
is required to clarify the relationship with ovarian 
  cancer risk.12
Increased plasma glucose levels have recently 
been  investigated  as  negative  prognostic  factors 
in  patients  with  neoplasms.  Our  study  evaluated 
plasma glucose levels in patients with various stages 
of cervical neoplasia. Patients with uterine cervi-
cal cancer stages I/II and III/IV had significantly 
higher plasma glucose levels than those with CIN 
or leiomyomas. Although some questions arising as 
does the glucose level decreases when they receive 
effective  treatment?  The  glucose  level  goes  up 
when they don’t have any treatment and the cancer 
progresses? Was body mass index measured? And 
were prediabetes patients excluded? A study limita-
tion is the inability to examine other demographic 
data,  since  the  study  analyzes  retrospective  data 
on a large time interval. Therefore, plasma glucose 
levels were divided into a cut-off level of 90 mg/dl 
for calculating the odds ratio, showing an increas-
ing trend in glucose levels with the development 
of cervical lesion. Thus, further prospective stud-
ies with a larger number of patients could enhance 
the relationship of glucose levels with prognosis of 
cervical cancer.
In conclusion, we have thus demonstrated an asso-
ciation between invasive cervical cancer and higher 
plasma glucose levels. This blood test is a compo-
nent of routine examination that should be used as 
an additional prognostic parameter in patients with 
cervical  neoplasia.  Further  studies  are  needed  to 
elucidate the value of plasma glucose levels in the 
evaluation of the progression and prognosis of uter-
ine cervical cancer.Plasma glucose and uterine cervical neoplasias
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